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Dietary polyphenols come mainly from plant-based foods including fruits, vegetables, whole grains, coﬀee, tea, and nuts.
Polyphenols may inﬂuence glycemia and type 2 diabetes (T2D) through diﬀerent mechanisms, such as promoting the
uptake of glucose in tissues, and therefore improving insulin sensitivity. This review aims to summarize the evidence from
clinical trials and observational prospective studies linking dietary polyphenols to prediabetes and T2D, with a focus on
polyphenol-rich foods characteristic of the Mediterranean diet. We aimed to describe the metabolic biomarkers related to
polyphenol intake and genotype-polyphenol interactions modulating the eﬀects on T2D. Intakes of polyphenols, especially
ﬂavan-3-ols, and their food sources have demonstrated beneﬁcial eﬀects on insulin resistance and other cardiometabolic
risk factors. Several prospective studies have shown inverse associations between polyphenol intake and T2D. The
Mediterranean diet and its key components, olive oil, nuts, and red wine, have been inversely associated with insulin
resistance and T2D. To some extent, these associations may be attributed to the high amount of polyphenols and bioactive
compounds in typical foods conforming this traditional dietary pattern. Few studies have suggested that genetic
predisposition can modulate the relationship between polyphenols and T2D risk. In conclusion, the intake of polyphenols
may be beneﬁcial for both insulin resistance and T2D risk.
1. Introduction
In the past few decades, type 2 diabetes (T2D), in parallel
with the obesity epidemic, has become a public health chal-
lenge for many countries [1]. Increasing evidence has dem-
onstrated that the combinations of several unhealthy
lifestyle factors, including a sedentary lifestyle, unhealthy
diets, overweight/obesity, smoking, and excessive alcohol
intake, were responsible for 90% of T2D cases [2]. For this
reason, strategies focused on lifestyle and the promotion of
a healthy diet to prevent T2D have been identiﬁed as a cor-
nerstone of researchers and policymakers.
Recently, growing interest has emerged on the beneﬁcial
eﬀects of plant-based diets for the prevention of chronic dis-
eases including obesity, diabetes, and cardiovascular disease
[3, 4]. Such diets are based on foods derived from plants,
including fruits, vegetables, whole grain cereals, legumes,
and nuts, with limited animal products. As an example, the
Mediterranean diet, which has been associated with many
health beneﬁts [5], is characterized by a high intake of fruits,
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vegetables, legumes, nuts, and olive oil; a moderate consump-
tion of dairy products and wine; and low intake of red and
processed meat, butter, cream, and sugar drinks. One of the
dietary constituents common in plant-based diets are poly-
phenols, which are especially abundant not only in fruits,
vegetables, whole grains, and legumes but also in cocoa, tea,
coﬀee, and red wine [6].
Polyphenols are a large andheterogeneousgroupofphyto-
chemicals containing phenol rings and are divided into ﬂavo-
noids, phenolic acids, stilbenes, and lignans [7] (Table 1).
Flavonoids are classiﬁed into ﬂavones, ﬂavonols, ﬂavanols,
ﬂavanones, isoﬂavones, and anthocyanins [8]. Among others,
fruits like apples, grapes, pears, and berries typically contain
high amounts of polyphenols (200–300mg per 100 g) [9].
The most common phenolic acids are caﬀeic acid and ferulic
acid, which is a major phenolic compound in coﬀee and
cereals, respectively [10]. The best-studied stilbene is resvera-
trol in grapes, grape products, and red wine [10]. Other
main dietary sources of polyphenols include vegetables,
chocolate, tea, whole grains, dry legumes, nuts, and olive
oil [10]. Polyphenols are the most abundant antioxidants
in the diet, and their intake has been associated with a
reduced incidence of T2D in humans [11–13]. Polyphenols
have anti-inﬂammatory eﬀects and may inﬂuence glycemia
through diﬀerent mechanisms, including the inhibition of
glucose absorption in the gut and the improvement of
insulin resistance [9].
This review aims to summarize the relevant evidence
linking dietary polyphenols to prediabetes and T2D with a
focus on polyphenol-rich food characteristics of the Mediter-
ranean diet (MedDiet). In addition, the present work aims to
describe genotype-polyphenol interactions and metabolic
biomarkers to understand the relationship between polyphe-
nols and T2D.
2. Dietary Polyphenols, Insulin Sensitivity, and
Resistance
Abundant evidence generated in human studies collectively
suggests that the intake of polyphenols and their major food
sources may exert beneﬁcial eﬀects on improving insulin
resistance and related diabetes risk factors, such as inﬂamma-
tion and oxidative stress (as reviewed by Scalbert et al. [9]).
Given the amount of such evidence, this narrative review
does not seek to provide a comprehensive summary of all
study ﬁndings, but rather focuses on well-conducted clinical
trials and observational prospective studies. In this regard,
only randomized and controlled trials have been considered,
and regarding the prospective cohort studies, only those with
appropriate control of potentially confounding variables
have been included. We have performed a narrative review
in MEDLINE up to June 2017. Our search terms combined
the exposures (polyphenols, ﬂavonoids, phenolic acids, stil-
benes, lignans; and also, MedDiet, extra-virgin olive oil, nuts,
and red wine) with several outcomes (insulin resistance,
insulin sensitivity, oxidation, inﬂammation, and T2D). We
also conducted a speciﬁc search for well-powered human
clinical studies with the potential for clinical translational
ﬁndings. We reviewed the evidence of polyphenols and
T2D from a nutritional genomic perspective, particularly
from metabolomics and metagenomics. We acknowledge
other omics studies using transcriptomics, proteomics, and
Table 1: Main food sources of polyphenols.
Polyphenol Compound Main food sources, excluding seasoning Main food sources, only seasoning
Total polyphenols
Coﬀee, oranges, apples, grapes, olives and
olive oil, red wine, cocoa powder, dark
chocolate, tea, black elderberry, nuts,
whole grains, legumes
Cloves, dried peppermint, star anise
Flavonoids Flavones
Virgin olive oil, oranges, whole grain wheat-
ﬂour bread, reﬁned-grain wheat-ﬂour bread,
whole grain wheat four, black olives
Celery seed, dried peppermint, dried,
common verbena
Flavonols Spinach, beans, onions, shallot Capers, saﬀron, dried oregano
Flavanols
Red wine, apples, peaches, cocoa powder,
nuts, dark chocolate
Flavanones
Grapefruit/pomelo juice, oranges, orange juice,
grapefruit juice
Dried peppermint, dried oregano,
fresh rosemary
Isoﬂavones Soy ﬂour, soy paste, roasted soy bean, beans Soy sauce
Anthocyanins
Cherries, red wine, olives, hazelnuts, almonds,
black elderberry, black chokeberry, blueberries
Phenolic acids Benzoic acid
Olives, virgin olive oil, red wine, walnuts,
pomegranate juice, red raspberry,
American cranberry
Chestnut, cloves, star anise
Cinnamic acid Coﬀee, maize oil, potatoes
Dried peppermint. Common verbena,
dried rosemary
Stilbenes Resveratrol Grapes, red wine, nuts
Lignans
Virgin olive oil, whole grain rye ﬂour,
bread from whole grain rye ﬂour, ﬂaxseed
Sesame seed oil, black sesame oil, ﬂaxseed
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epigenomics may also have an important role on understand-
ing polyphenol mechanisms of action, but given the clinical
translational nature of this review, we have not included
these studies.
Among all polyphenols, the beneﬁcial eﬀects of ﬂavanols
(ﬂavan-3-ols) and their primary food sources, including
cocoa, chocolate, and red wine, have been most widely exam-
ined in clinical trials. In a meta-analysis of 24 trials among
1106 individuals that examined the eﬀects of cocoa intake
for 2–18 weeks, Shrime et al. showed signiﬁcant eﬀects of
cocoa intake on improving insulin sensitivity [14]. Homeo-
static model assessment of insulin resistance (HOMA-IR)
decreased by 0.94 points (95% CI=0.59, 1.29; P < 0 001) with
the consumption of ﬂavonoid-rich cocoa. This meta-analysis
included healthy participants and patients with hyperten-
sion, diabetes, and overweight. Total ﬂavonoid intake ranged
from 16.6mg/d to 1080mg/d and control group included
low-ﬂavonoid cocoa, white chocolate, skimmilk, and placebo
capsules. In nine studies, at least one author was employed by
a chocolate company [14]. In another meta-analysis of 42 tri-
als comprised of 1297 individuals which was conducted in
2012, Hooper et al. showed that acute to short-term (≤18
weeks) intake of cocoa, chocolate, and ﬂavan-3-ols signiﬁ-
cantly decreased insulin resistance [15]. Healthy participants
and participants with elevated blood pressure, serum choles-
terol, and diabetes as well as other health conditions were
included. Interventions were cocoa drinks, dark or milk
chocolate, cocoa supplements, solid chocolate plus cocoa
drinks, and a whole diet (all foods provided) including cocoa
powder and chocolate. These were compared with low
ﬂavan-3-ol versions of the same foods, drinks, or supple-
ments [15].
Data on the eﬀects of long-term chronic consumption
of ﬂavan-3-ols on cardiometabolic health are scarce. In a
randomized, placebo-controlled trial in 93 patients with
T2D, the intake of 7 grams per day of ﬂavonoid-
enriched chocolate (containing 850mg ﬂavan-3-ols and
100mg isoﬂavones) for 1 year signiﬁcantly improved insu-
lin resistance. In this long-term trial, eﬀects on hemoglo-
bin A1c (HbA1c) and glucose were not observed [16].
However, the authors acknowledged that the dropout rate
was high and limited to postmenopausal women receiving
diabetes therapy.
Another food source of ﬂavan-3-ols, green tea, has also
been extensively examined in short-term clinical trials evaluat-
ing its beneﬁcial eﬀects on cardiometabolic health. For example,
catechins from green tea exerted beneﬁcial eﬀects on lowering
fasting glucose, although eﬀects on fasting insulin, HbA1c,
and HOMA-IR were not signiﬁcant in a meta-analysis summa-
rizing results of 22 randomized clinical trials with 1584 partic-
ipants and ranging interventions from 3 to 24 weeks [17].
Green tea catechin dosage ranged from 240mg/d to 1207mg/
d and was compared with water or placebo.
Clinical trials that aim to assess the eﬀects of anthocya-
nins are relatively sparse. In a double-blinded 6-week clinical
trial among 32 obese nondiabetic individuals, Stull et al.
found that intake of a smoothie with added blueberry powder
(equivalent to 668mg/day anthocyanins) as compared to a
smoothie of equal nutritional value without added blueberry
bioactivities signiﬁcantly improved insulin sensitivity mea-
sured by a hyperinsulinemic-euglycemic clamp [18]. Beneﬁ-
cial eﬀects of anthocyanins (either puriﬁed anthocyanin
(320 mg/d) derived from bilberry and black currant or pla-
cebo) on improving insulin resistance were also observed in
a 12-week trial conducted in 74 patients with nonalcoholic
fatty liver disease [19]. Of note, the descriptions of the
control foods and extracts used as in the abovementioned
clinical trials were poorly described and no indication on
its nature is given.
The consumption of beverages with added freeze-dried
strawberries rich in anthocyanins compared to placebo for
12 weeks did not exert eﬀects on inﬂammatory markers or
glucose measurements in 60 individuals with abdominal adi-
posity and hypercholesterolemia, although a signiﬁcant
reduction of total and low-density lipoprotein (LDL) choles-
terol was observed in this trial [20].
Isoﬂavones are a class of ﬂavonoids with estrogenic
eﬀects that are found in soya beans and are highly consumed
in East Asian populations. Probably because of these estro-
genic properties, most of the clinical trials evaluating the
eﬀects of isoﬂavone supplementation focused on postmeno-
pausal or perimenopausal women. In a meta-analysis of 24
trials comprised of 1518 men and women, intervention
groups included isoﬂavone extracts as supplements and
whole soy foods into the diet and compared the isolated soy
protein that contained isoﬂavones with milk or animal pro-
tein. The soy protein content ranged from 0 to 40 g soy pro-
tein/d, and the isoﬂavone content ranged from 36 to 132mg
isoﬂavones/d. Results from this meta-analysis have shown
that soy intake did not exert signiﬁcant eﬀects on measures
of glucose metabolism, including fasting glucose and insulin,
HOMA-IR, HbA1c, and 2-hour glucose or insulin levels [21].
Restricting the analysis to postmenopausal women generated
similar results.
Interestingly, in another meta-analysis that only con-
sidered clinical trials conducted among non-Asian peri-
menopausal or postmenopausal women, soy isoﬂavones
or genistein supplements for 3 months to 2 years signiﬁ-
cantly reduced serum insulin and HOMA-IR, but had no
eﬀects on fasting blood glucose [22].
Lignans are a group of polyphenols that also possess
estrogenic properties. A few trials have been conducted to
elucidate the eﬀects of ﬂaxseed supplements that contain
high amount of lignans on insulin resistance and other
cardiometabolic intermediate outcomes. In a small crossover
trial among 9 obese subjects with glucose intolerance, ﬂax-
seed intake (40 g/day) compared to 40 g wheat bran for 12
weeks signiﬁcantly improved insulin resistance [23]. In
another small randomized trial comparing ﬂaxseed intake
(40 g/day) with hormone replacement therapy among 25
postmenopausal women, ﬂaxseed intake signiﬁcantly
reduced glucose and insulin levels, although these beneﬁts
were comparable to those of hormone replacement therapy
[24]. However, sample sizes of these studies were small and
replication of the results in other populations is needed to
make strong conclusions. In a crossover, randomized trial
conducted among ~70 patients with T2D, Pan et al. showed
that supplementation of 360mg/day of lignans derived from
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ﬂaxseed for 12 weeks signiﬁcantly reduced HbA1c [25] and
C-reactive protein (CRP) [26] in comparison with the pla-
cebo group. Interestingly, such eﬀects were primarily
observed in women, whilst no eﬀects on CRP levels were
found in men [26]. In the largest trial testing the eﬃcacy of
ﬂaxseed supplements so far, ﬂaxseed lignan supplements
(543mg/day) (as compared to placebo) did not exert signif-
icant eﬀects on lowering fasting blood glucose concentra-
tions or inﬂammatory markers in 100 Canadian healthy
men and women followed for 6 months [27]. Moreover,
in a recent trial among 99 prediabetic patients, ﬂaxseed
supplementation did not improve insulin sensitivity [28].
This randomized, clinical trial compared two groups receiv-
ing 40 g and 20 g per day of ﬂaxseed powder daily for 12
weeks and the third group was the control group (no inter-
vention) [28].
Evidence regarding other polyphenols or their food
sources is sporadic. In a crossover trial conducted in over-
weight men and women, supplementation of 150mg/day res-
veratrol compared to placebo capsules for 4 weeks had no
eﬀects on insulin sensitivity or inﬂammatory markers [29].
Supplements of chlorogenic acid (1g/d, a polyphenol highly
present in coﬀee, signiﬁcantly reduced glucose and insulin
concentrations 15 minutes following an oral glucose tolerance
test (OGTT), although no overall improvement on OGTT
measurements was observed in a small crossover trial (three
interventions: 12 g decaﬀeinated coﬀee, 1 g chlorogenic acid,
500mg trigonelline, and placebo (1g mannitol)) including 15
overweight men [30]. Of note, trials that examined the eﬀects
of coﬀee consumption per se did not generate consistent ﬁnd-
ings regarding whether insulin resistance could be improved,
although all these trials were small in sample size (ranging
from 10 to 47 participants) [31–33]. Of note, because the por-
tions of coﬀee are larger in North European and American
populations and therefore the intake of polyphenols from this
food greater, some diﬀerences may exist among populations.
In summary, intake of polyphenols, especially ﬂavan-3-
ols and their food sources, have demonstrated overall beneﬁ-
cial eﬀects on decreasing insulin resistance, chronic system-
atic inﬂammation, oxidative stress, and improving other
cardiometabolic risk factors. However, some publication bias
may be present as several clinical trials have been sponsored
by the food industry, particularly for cocoa, chocolate, and
tea, and this may explain the greater amount of evidence on
this food groups. In addition, some clinical trials on this topic
were of short duration which may dilute the eﬀect of poly-
phenol intake on a long term. Although surrogate endpoints
measured in most clinical trials can help to monitor changes
during follow-up and are relevant for the prediction of T2D,
more research is warranted to elucidate the metabolic eﬀects
of polyphenols in larger trials with longer intervention term
and risk of T2D. In this regard, the ongoing Cocoa Supple-
ment and Multivitamin Outcomes Study (COSMOS) [34],
which aims to evaluate the eﬃcacy of a concentrated cocoa
extract using a ﬁve-year randomized trial among 18,000
healthy men and women, may provide conclusive evidence
on the health beneﬁts of cocoa (rich in polyphenols) on car-
diometabolic hard outcomes. Finally, novel metabolomic
techniques will help to determine more objective plasma
concentrations of polyphenols and had a better picture of
availability and potential beneﬁcial eﬀects on insulin resis-
tance and T2D.
3. Dietary Polyphenols and Risk of Type 2
Diabetes
Table 2 summarizes the evidence on prospective studies eval-
uating polyphenol intake and risk of T2D. Several studies
have evaluated the associations between the intake of total
ﬂavonoids or speciﬁc ﬂavonoids and the risk of T2D. Four
studies including data from 6 cohorts on healthy participants
have evaluated the associations between dietary total ﬂavo-
noids and risk of T2D [35]. Results from a meta-analysis
including 18,146 incident T2D cases and 284,806 partici-
pants showed that the relative risk of T2D for the highest
intake of total ﬂavonoids compared with the lowest was
0.91 (95% CI: 0.87, 0.96). A dose-response analysis of these
results revealed that 500mg/d increase in total ﬂavonoid
intake was associated with a signiﬁcant 5% reduction of
T2D incidence. These beneﬁcial eﬀects were especially
observed in younger individuals and in those studies with
larger follow-up [35]. Two new studies not included in this
meta-analysis were published later [36, 37]. In the European
Prospective Investigation into Cancer and Nutrition-
InterAct (EPIC-InterAct) study, an inverse association
between total ﬂavonoid intake and T2D risk was reported
in a case-cohort study including 12,403 incident cases of
diabetes and 16,154 healthy participants [36]. In contrast,
total ﬂavonoid intake was nonsigniﬁcantly associated with
the risk of T2D in a report from the Framingham Oﬀspring
Study, which included 2915 participants followed for 11.9
years [37].
Several studies have evaluated the association between
the consumption of diﬀerent subtypes of ﬂavonoids and
T2D risk with some controversial results. The FinnishMobile
Clinic Health Examination Survey (FMCHES) [38], the
Womens’ Health Study [39], both including healthy partici-
pants, and the α-Tocopherol, β-Carotene Cancer Prevention
(ATBC) Study, which included male smokers [40], examined
the associations between the intake of total or selected ﬂavo-
nol or ﬂavone molecules (quercetin, kaempferol, myricetin,
hesperetin, and naringenin) and T2D risk. In the FMCHES,
higher intake of quercetin and myricetin showed a trend
towards a reduction in the risk of T2D, but not for the rest
of the compounds [38]. No signiﬁcant associations were
observed between total or selected types of ﬂavonol and ﬂa-
vone intake and T2D in the Women’s Health Study [39]
and the ATBC Study cohorts [40].
Findings from large-scale prospective studies have evalu-
ated the associations between ﬂavonoids and T2D risk. After
pooling the results of three large cohorts (Nurses’ Health
Study (NHS), NHSII and Health Professionals Follow-up
Study (HPFS); 3,645,585 person-years of follow-up; 12,611
incident cases of diabetes), higher intakes of anthocyanins
and anthocyanin-rich fruits were associated with a decreased
risk of T2D after adjusting for multiple potential con-
founders, whereas no associations were shown for total ﬂavo-
nols, ﬂavones, ﬂavanones, and ﬂavan-3-ols [11]. A case-
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cohort study within the frame of the EPIC-InterAct cohort,
which included healthy middle-aged participants from eight
countries, showed that when comparing extreme quintiles
of consumption of ﬂavonoid subclasses, total ﬂavonols and
ﬂavanols, including ﬂavan-3-ol monomers, were inversely
related to the diabetes risk, whereas no associations were
reported for the intake of lignans [36]. It is important to
highlight that these associations were observed within the
context of a European-wide population with a large heteroge-
neity in the intake of these compounds. In a following report
from the same study [41], signiﬁcant inverse trends for the
intakes of proanthocyanidin dimers and trimers and incident
T2D were observed, but not for proanthocyanidins with a
greater polymerization degree. Among the ﬂavonol sub-
classes, only myricetin was associated with a lower incidence
of T2D [41]. Finally, in the Framingham Oﬀspring Cohort,
each 2.5-fold increase in ﬂavan-3-ol intake was marginally
associated with an 11% lower incidence of T2D, but no other
associations between other ﬂavonoid classes (ﬂavonols, ﬂa-
vones, ﬂavanones, anthocyanins, and polymeric ﬂavonoids)
and risk of T2D were reported [37].
In relation to the intake of isoﬂavones, ﬁndings from the
NHS, NHSII, and HPFS have shown inverse associations for
total isoﬂavones and major individual isoﬂavones, especially
those present in soy and soy products, including daidzein
and genistein, with the risk of developing diabetes [42]. How-
ever, no signiﬁcant association between total isoﬂavone
intake and T2D has been reported in the EPIC-InterAct
Study [36].
In summary, results from prospective cohort studies have
suggested inverse associations between the intake of total ﬂa-
vonoids and speciﬁc ﬂavonoid subclasses and the risk of T2D
although some controversial results exist.
4. Characteristic Polyphenols of the
Mediterranean Diet, Prediabetes,
and Type 2 Diabetes
As described before, dietary polyphenols come mainly from
plant-based foods [8].Olive oil, nuts, redwine, legumes, fruits,
and vegetables, key components of the MedDiet, are all
polyphenol-rich foods [5]. The much-appreciated MedDiet
is well-known for its antioxidant and anti-inﬂammatory
eﬀects [43, 44]. The cardioprotective eﬀect of this dietary pat-
tern has been attributed, in part, to the high amount of antiox-
idant components such as the phenolic compounds [43].
Moreover, the MedDiet has been shown to be beneﬁcial for
glycemic control and T2D [45, 46]; however, few studies have
evaluated the eﬀects of speciﬁc polyphenols from food prod-
ucts characteristic of this diet and insulin resistance or T2D.
In this section, we aim to provide further information on
characteristic food of the MedDiet that contain large
amounts of polyphenols.
4.1. Extra-Virgin Olive Oil. Extra-virgin olive oil is probably
one of the components that most diﬀerentiates the MedDiet
from other dietary patterns. Phenolic components such
as oleuropein and hydroxytyrosol, ﬂavonoids, specially ﬂa-
vones, and lignans are abundant in extra-virgin olive oil
[47]. Extra-virgin olive oil is the best quality olive oil, is
rich in taste and color, and also contains high amount of
bioactive compounds compared to other types of olive
oil (such as common olive oil, which is reﬁned, has less
ﬂavor, color, and aroma, and contains fewer amounts of
antioxidants and vitamin E). The phenolic composition
of olive oil ranges from 50 to 800mg/L depending on sev-
eral factors like the variety, cultivation techniques, degree
of ripeness, and climate, among others [48].
Evidence from clinical trials on the eﬀects of olive oil
polyphenols and biomarkers of T2D is scarce. Only two ran-
domized trials have been published so far evaluating the
eﬀect of olive leaf polyphenols on markers of insulin sensitiv-
ity [49, 50]. Main polyphenols in olive leaves (oleuropein and
hydroxytyrosol) are similar than those in fruit and fruit oil;
however, its concentration is greater. In the ﬁrst intervention
study, including 70 adults with T2D, those participants con-
suming olive leaf extract (500mg) exhibited signiﬁcantly
lower HbA1c and fasting plasma insulin levels; however,
postprandial plasma insulin levels did not diﬀer signiﬁcantly
by treatment group [50]. The second study demonstrated
that participants who received capsules of olive leaf extract
for 12 weeks (51.1mg oleuropein and 9.7mg hydroxytyrosol
per day) compared to placebo improved pancreatic β-cell
function by 28% and also signiﬁcantly improved insulin sen-
sitivity compared to the placebo [49]. Other clinical trials
have evaluated the eﬀect of extra-virgin olive oil rich in poly-
phenols on glycemic biomarkers [51, 52]. Daily consumption
of polyphenol-rich extra-virgin olive oil for 8 weeks signiﬁ-
cantly reduced fasting plasma glucose and HbA1c, as well
as other circulating inﬂammatory adipokines, in overweight
patients with T2D [52]. In contrast, no signiﬁcant eﬀects on
fasting glucose after supplementation with 20mL per day of
polyphenol-rich olive oil during 6 weeks compared to
20mL dose of low phenolic oil were observed in healthy par-
ticipants [51]. The PREDIMED trial has provided conclusive
evidence of the beneﬁcial eﬀects of a MedDiet supplemented
with extra-virgin olive oil on glucose metabolism and T2D
[45, 46]. In this regard, a MedDiet supplemented with
extra-virgin olive oil reduced the risk of T2D by 40% (HR:
0.60; 95% CI: 0.43, 0.85) after a median of 4.1 years of
follow-up among participants at high cardiovascular risk
compared to the control group [46]. Previous reports from
the PREDIMED Study also showed that a MedDiet supple-
mented with extra-virgin olive oil reduced fasting plasma
glucose improved insulin resistance and inﬂammatory bio-
markers [45, 53]. Another randomized crossover trial in
healthy volunteers, the EUROLIVE study, which tested the
eﬀect of the daily 3-week administration of 25mL of 3 olive
oils with low, medium, and high phenolic content, demon-
strated beneﬁcial eﬀects of phenolic compounds on oxidative
damage on lipids and HDL cholesterol [54]. However, given
that the volunteers were healthy, no eﬀects were observed
on glucose levels; nevertheless, the objective of the study
was the lipid and lipoperoxidation. Also in a postprandial
state study with healthy volunteers, after 50mL of virgin
olive oil load, the expression of candidate genes related
to insulin sensitivity was observed in peripheral mononu-
clear cells [55].
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4.2. Nuts.Nuts, which are well-known for their unique nutri-
tional composition (rich in unsaturated fatty acids, ﬁber,
antioxidant vitamins, minerals, and other bioactive com-
pounds), are also consumed in high amounts in the MedDiet.
Several seeds and nuts are among the richest sources of poly-
phenols: chestnuts andwalnuts are rich in ellagitannins; while
hazelnuts, pecan, and almonds are rich in proanthocyanidins;
and ﬂaxseed is rich in lignans [8]. Although the eﬀects of nut
consumption on glycemic markers and T2D have been well
studied over the past decades [56, 57], speciﬁc studies on poly-
phenols from nuts are lacking. However, we have some indi-
rect evidence that polyphenols from tree nuts may have
beneﬁcial eﬀects on glucose metabolism. Some evidence has
suggested that ellagic acid, which is found in a considerable
amount in several nuts (especially walnuts), could be beneﬁ-
cial for diabetes control [58]. In addition, urolithin A glucu-
ronide in plasma, a metabolite of dietary ellagic acid
derivatives which has shown to be a discriminative bio-
marker of nut exposure, was inversely correlated with insulin
resistance measured by HOMA-IR. However, further clinical
trials are needed to conﬁrm these associations [59].
4.3. Red Wine. One of the main characteristics of the tradi-
tional MedDiet is the moderate intake of wine consumed
with meals. Wine, particularly red wine, is rich in phenolic
compounds including ﬂavonoids (anthocyanins, tannins,
and catechin), stilbenes like resveratrols, tyrosols, and
hydroxytyrosols. Evidence suggests that red wine con-
sumption exerts some beneﬁts on cardiovascular health
[60]; however, whether these eﬀects are due to ethanol
or to nonalcoholic components of red wine is still unclear.
Along these lines, a randomized clinical trial including
sixty-seven men at high cardiovascular risk was designed
to compare the eﬀects of moderate intake during 4 weeks
of red wine, a high polyphenolic alcoholic beverage (the
equivalent amount of dealcoholized wine), a high polyphe-
nolic nonalcoholic beverage, and gin (without polyphenols)
on glucose metabolism and lipid proﬁle [61]. Findings of
that study suggested that red wine rich in polyphenols with
or without alcohol, but not gin, improved glucose metabo-
lism, as measured by HOMA-IR [61]. Previous clinical tri-
als have demonstrated improvements in insulin sensitivity
with the consumption of red wine [62] and red grape juice
[63], but others reported no signiﬁcant eﬀects on these
parameters [64, 65]. In addition, the positive eﬀects on glu-
cose metabolism of supplementation with grape derived
polyphenol and resveratrol, one of the main polyphenols
in red wine, have been observed in intervention studies
[66, 67]. Finally, a 2-year randomized clinical trial in
patients with T2D suggests that initiating moderate red
wine intake, among well-controlled diabetics as part of a
healthy diet, is apparently safe and modestly decreases
cardiometabolic risk [68]. Moreover, genetic interactions
may play a role in glucose metabolism, and red wine’s
eﬀects also involve nonalcoholic constituents such as poly-
phenols. In this trial, slow ethanol metabolizers (alcohol
dehydrogenase alleles [ADH1B∗ 1] carriers) signiﬁcantly
beneﬁted from the eﬀect of red wine on glycemic control
(fasting plasma glucose, HOMA-IR, and hemoglobin A1c)
compared with fast ethanol metabolizers (persons homozy-
gous for ADH1B∗ 2) [68].
4.4. Other. Fruits, vegetables, whole grains, legumes, and cof-
fee are also primary sources of polyphenols [8] and are ben-
eﬁcial for glycemic control and prevention of T2D [4, 69].
Other beverages and foods that are rich in polyphenols
include green tea, soy, chocolate, and cocoa and could also
play a role in the prevention of T2D [70].
In summary, the MedDiet and its key components, extra
virgin olive oil, nuts, and red wine, are inversely associated
with insulin resistance and T2D. To some extent, these eﬀects
may be attributed to its high amount of polyphenols and
other bioactive compounds.
5. New Frontiers in Nutrition Research:
Genotype-Polyphenol Interaction on
Type 2 Diabetes
Because of their chemical structures, dietary polyphenols
exert multiple activities by interacting with several molecular
pathways particularly relevant for glucose homeostasis. In
Figure 1, we summarize relevant mechanisms linking dietary
polyphenols and T2D risk. These include slowing carbohy-
drate digestion and glucose absorption, stimulation of insulin
secretion, modulation of glucose release, and activation of
insulin receptors and glucose uptake in the insulin-sensitive
tissues [71]. A growing body of evidence from in vitro and
animal studies has shown that polyphenols can activate
and/or silence transcription factors, and consequently inﬂu-
ence gene expression, and regulate diﬀerent signaling path-
ways in the muscle, the liver, pancreatic β-cells, the
hypothalamus, and adipose tissue, thereby contributing to
glucose homoeostasis [72, 73].
Although promising data aimed at understanding how
diﬀerent polyphenol classes can modulate genetic regulation
and expression have been published, few studies have inves-
tigated whether genetic predisposition modiﬁes the relation-
ship among polyphenols, intermediate phenotypes of insulin
resistance, and T2D risk [74–79]. An initial and very prelim-
inary track of evidence for genotype-polyphenol interaction
is emerging from studies of coﬀee, the consumption of which
is highly spread in Mediterranean regions. In a prospective
population-based cohort study including 4077 normal glyce-
mic individuals over a 4-year follow-up, habitual coﬀee
intake outweighed the hazard of unfavorable genetic predis-
position on 3 well-known T2D-increasing risk genetic loci,
including IGF2BP2, CDKAL1, and KCNJ11 [74]. Along
these lines, an independent study including 1180 nondia-
betic young to middle-aged participants with stage 1
hypertension, baseline coﬀee consumption was longitudi-
nally associated with the risk of impaired glucose tolerance
only in carriers of CYP1A2∗ 1F allele. Among participants
homozygous for the ∗ 1A allele, which is responsible for
fast caﬀeine metabolism, the favorable action of polyphe-
nols or other bioactive agents balanced the genetic and
metabolic risk for T2D [75]. Finally, in a prospective epi-
demiological study from the EPIC-InterAct cohort, includ-
ing 8086 incident T2D cases in 11,035 participants over
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12.5 years, habitual coﬀee consumption was associated
with a 7% T2D risk reduction among carriers of the diabe-
tes increasing risk allele at transcription factor 7-like 2
locus (TCF7L2) [76]. In addition, an interaction between
an incretin-speciﬁc genetic risk score, designed to capture
the genetic predisposition to defects in postprandial insu-
lin secretion and coﬀee consumption on T2D risk was
observed (i.e., each additional cup of coﬀee was associated
with 5% lower T2D risk in individuals carrying high num-
ber of risk alleles). In line with previous results, adherence
to the MedDiet has been reported to be able to reduce the
adverse eﬀect of the TCF7L2 polymorphism on fasting
glucose and blood lipids and, importantly, on stroke inci-
dence [77]. Unfortunately, with this type of study, we can-
not diﬀerentiate the eﬀect of polyphenols from other
dietary compounds of the MedDiet.
Despite nutrigenomic evidence being still preliminary,
and major challenges existing in analytical strategies and rep-
lication, the role of polyphenol-rich components on TCF7L2
locus is likely to be relevant. TCF7L2 is the strongest com-
mon genomic region associated with T2D (OR=1.4) and
encodes a transcription factor for proteins involved in the
proper functioning of the Wnt signaling pathway, essential
for insulin secretion and beta-cell proliferation [78, 79]. It
would be rational, therefore, to envision that nutrients which
tend to stimulate both insulin and incretin secretion will tend
to partly compensate for any genetic defects in the incretin
system and thus confer higher protection from T2D in indi-
viduals carrying the predisposing polymorphisms. Under-
standing gene-diet interactions in T2D holds promise to
achieve the goal to develop personalized diet and lifestyle
interventions based on genetic proﬁle; nevertheless, further
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Figure 1: Relevant mechanisms linking dietary polyphenols and T2D risk. Polyphenols can exert a beneﬁcial eﬀect on type 2 diabetes by a
number of mechanisms including (a) slowing carbohydrate digestion and glucose absorption by interacting with oral cavity and intestinal
α-amylase and intestinal α-glucosidase and sodium-dependent glucose transporter (SLGT1); (b) stimulating insulin secretion in the
pancreas via increasing 5′adenosine monophosphate-activated protein kinase (AMPK) pathway, and insulin receptor substrate (ISRS) and
decreasing β-cell oxidative damage which preserves β-cell integrity; (c) modulating liver glucose release due to increase in acyl-CoA
oxidase 1 (ACO-1) and carnitine palmitoyl transferase 1-β (CPT1-β) and diminishing glucose 6 phosphatase (G6Pase) and
phosphoenolpyruvate carboxylase (PEPCK); and (d) activation of glucose uptake receptors in the insulin-sensitive tissue. Additionally, the
modulation of microbial metabolism can synergically beneﬁt glucose homeostasis.
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research is warranted before implementing preliminary
results to clinical practice is still required.
6. Biomarkers of Polyphenol Intake
Along with the development of sophisticated genomics tech-
niques, recent advancements in analytic procedures have
allowed the measurement of molecules that provide a close
representationofwhat is encodedby thegenomeandmodiﬁed
by diet, gut microbiome, and other environmental exposures
[80]. In this regard, metabolomics has greatly contributed in
the identiﬁcation of new biomarkers (of dietary exposure,
nutritional status, and health/disease). In a prospective nested
case-control study including 1107 diabetic women and 1107
controlwomenparticipating in theNHS,metabolites fromdif-
ferent classes of polyphenols were associated with T2D risk.
For example, urinary excretion of enterolignans, especially
enterolactone, was signiﬁcantly associated with a lower T2D
risk during up to 13 years of follow-up [12]. Comparing the
extreme quartiles of urinary excretion of enterolactone, the
relative risk of T2D was 0.62 (95% CI: 0.44, 0.88; P for
trend= 0.003). In contrast, metabolites from ﬂavanones
(naringenin and hesperetin), ﬂavonols (quercetin and iso-
rhamnetin), and phenolic acids (caﬀeic acid) in spot urine
samples were signiﬁcantly associated with a lower T2D risk
within a relatively short period of follow-up (≤4.6 years) after
sample collection, but not during the entire follow-up [81].
Such a temporal pattern may be explained by the signiﬁcant
variability of thesemetabolites over time, especially when they
aremeasured in spot urine samples [81]. In a separate analysis,
Ding et al. found an inverse associationbetweenurinary excre-
tion of daidzein and genistein, but not other isoﬂavonemetab-
olites, and T2D risk in the NHS and NHSII [82]. An inverse
association between isoﬂavone biomarkers and diabetes risk
was also observed in twoother prospective analyses conducted
among minority populations. Among 431 Native American
participating in the Strong Heart Family Study [83], Zhao
et al. used an untargeted metabolomics approach to examine
metabolite levels in plasma. From seven metabolites related
to diabetes risk after adjustment by multiple testing, an isoﬂa-
vone metabolite [(3S)-7-hydroxy-2′,3′,4′,5′,8-pentamethoxyi-
soﬂavan] was identiﬁed as being signiﬁcantly associated with
a lower risk [83]. Moreover, in 1391 Koreanmen and women,
higher plasma concentrations of genistein were signiﬁcantly
associated with a lower T2D risk among women who were
equol producers, which is a metabolite of isoﬂavone, but not
in men or nonequol producers [84]. Although equol is bio-
transformed from daidzein by the metabolism caused by gut
bacteria, some individuals cannot metabolize daidzein to
equol. There is increasing evidence that the endocrine-
related clinical eﬃcacy of isoﬂavone may be modiﬁed by
equol-producing status [84].
A recent prospective analysis conducted in the PRE-
DIMED trial showed that over a 5-year follow-up,
increased total polyphenol excretion was signiﬁcantly asso-
ciated with lower levels of triglycerides, glucose, and dia-
stolic blood pressure among 573 participants at high
cardiovascular risk [85]. In a small cross-sectional analysis
conducted among 57 Japanese women, higher plasma levels
of chlorogenic acid were signiﬁcantly associated with lower
levels of fasting blood glucose, HbA1c, and CRP [86]. In
the nationwide representative National Health and Nutri-
tion Examination Survey (NHANES), urinary excretion of
enterolignans was inversely associated with CRP levels
and metabolic syndrome components [87–89].
7. Metagenomics
Another layer of complexity in human nutritional studies
comes from the intricate interplay between the gut micro-
biome and dietary intake. Obesity, insulin resistance, and
T2D have been correlated with an altered gut microbiota com-
position. The largest metagenomics-based study to date,
which includes 368 Chinese individuals, identiﬁed a moderate
degree of gut bacterial dysbiosis with a decline in butyrate-
producing bacteria and an increase in opportunistic bacteria
among T2D patients as well as an enrichment of other micro-
bial functions conferring sulphate reduction and oxidative
stress resistance [90]. This is particularly relevant because only
a limited number of bacterial species have been identiﬁed as
being involved in the metabolism of polyphenols [91].
The 3-week consumption of a phenolic compounds
enriched virgin olive oil, containing a mixture of olive oil
and thyme phenolic compounds, decreases systemic oxidized
LDL and increases biﬁdobacterium population and microbial
metabolites of phenolic compound in faeces from hypercho-
lesterolemic humans [92]. However, this was a small ran-
domized controlled trial only including 12 participants.
For instance, in vitro digestion of water-insoluble cocoa
fractions to investigate the biotransformation of polyphe-
nols demonstrated that bacterial fermentation of the insoluble
material was associated with an increase of biﬁdobacteria and
lactobacilli as well as butyrate production [93]. Flavanols were
converted intophenolic acids by themicrobiota resulting in an
increasing concentration of 3-hydroxyphenylpropionic acid
[93]. In a separate randomized clinical trial, these microbial
changes were associated with signiﬁcant reductions in plasma
triacylglycerol and C-reactive proteins, suggesting the poten-
tial beneﬁts associated with the dietary inclusion of ﬂavanol-
rich foods [94].
Undoubtedly, the interplay between gut microbiome and
host and its modulation by nutrition will beneﬁt from the
integration of information from a biology-wide systems
approach. Integration of gene sequence, metabolomics, and
other “omics” sources will pave the way towards a better
molecular understanding of the complex organisms.
System-wide computational approaches will aid testing
mechanistic hypothesis in silico on whole systems, such as
eﬀects of diet and modulations of metabolic diseases.
8. Conclusions
In the past decades, active strategies for the prevention of
T2D focusing on healthy diets, and lifestyle in general, have
become a priority for researchers and policymakers. Growing
interest has particularly emerged on the beneﬁcial eﬀects of
plant-based diets for the prevention of chronic diseases
such as obesity and diabetes [4]. Polyphenols are highly
12 Oxidative Medicine and Cellular Longevity
prevalent in plant-based diets, such as the MedDiet, and
especially abundant in fruits, vegetables, legumes, cocoa,
coﬀee, and red wine [7]. In addition, extra-virgin olive
oil and nuts, both key components of the MedDiet, are
also polyphenol-rich foods.
Given the abundant evidence from human studies regard-
ing the intake of polyphenols, and their food sources, on
related-diabetes risk factors, this narrative review has focused
on well-conducted clinical trials and prospective cohort stud-
ies with special attention paid to extra-virgin olive oil, nut,
and red wine consumption but also other polyphenol-rich
foods. These key components of the MedDiet were inversely
associated with insulin resistance and T2D risk in observa-
tional studies [46]. The intake of speciﬁc polyphenols, espe-
cially ﬂavan-3-ols and their food sources, has demonstrated
overall beneﬁcial eﬀects on improving insulin resistance,
chronic systemic inﬂammation, oxidative stress, and other
cardiometabolic risk factors in trials that tested eﬀects of acute,
moderate-term, or relatively long-term (up to a year) intake of
ﬂavan-3-ols [14–16]. Moreover, ﬁndings from prospective
cohort studies have suggested inverse associations between
the intake of total ﬂavonoids and speciﬁc ﬂavonoid subclasses
and the risk of T2D [13, 35–37], although some controversial
results still exist.
Given the chemical structures of dietary polyphenols,
multiple bioactivities are displayed by interacting with
molecular pathways particularly relevant for glucose homeo-
stasis. A preliminary track of evidence for genotype-
polyphenol interaction is emerging from coﬀee consumption
and beneﬁts on glycemia control [74]. In addition, adherence
to the MedDiet, a polyphenol-rich dietary pattern, has been
shown to reduce the adverse eﬀect of the TCF7L2 polymor-
phism on fasting glucose [77]. The role of polyphenol-rich
foods on TCF7L2 locus is therefore likely to be relevant.
The advancement in sophisticated omics methodologies
has allowed the determination of molecules involved in the
nutritional genomics (genetic/epigenetic, transcriptome/epi-
genomics, proteome, and metabolome), metagenomics, and
other environmental exposures, but mainly as markers of
compliance. Therefore, the integration of gene sequencing
and omics techniques will lead towards a molecular under-
standing of the complex organisms. System-wide computa-
tional approaches will thus contribute to the study of the
eﬀects of diet on modulation of metabolic diseases by testing
the hypothetical mechanisms in silico on whole systems.
In conclusion, the intake of polyphenols may be beneﬁ-
cial for both insulin resistance and T2D risk.
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